공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 증상 기반 다중진단 시장 : COVID-19의 영향, 전략 및 동향 : 증후군(호흡기, 패혈증, 위장관 등), 장소, 제품, 국가별 예측 : 시장 분석, 경영 가이드 및 커스터마이제이션(2021-2025년)

Syndromic Multiplex Diagnostic Markets with Covid-19 Impacts. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, Gi Etc.) by Place, by Product and by Country. with Market Analysis, Executive Guides and Customization. 2021 to 2025

리서치사 Howe Sound Research
발행일 2021년 09월 상품 코드 1028764
페이지 정보 영문 501 Pages
가격
US $ 6,995 ₩ 8,280,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 12,423,000 PDF (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 16,567,000 PDF (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 증상 기반 다중진단 시장 : COVID-19의 영향, 전략 및 동향 : 증후군(호흡기, 패혈증, 위장관 등), 장소, 제품, 국가별 예측 : 시장 분석, 경영 가이드 및 커스터마이제이션(2021-2025년) Syndromic Multiplex Diagnostic Markets with Covid-19 Impacts. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, Gi Etc.) by Place, by Product and by Country. with Market Analysis, Executive Guides and Customization. 2021 to 2025
발행일 : 2021년 09월 페이지 정보 : 영문 501 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

COVID-19의 유행은 감염 진단의 새로운 세계 도래를 알렸습니다. 감염 진단은 변화하고 있으며, 앞으로도 더욱 변화해 나갈 것입니다.

증후군 검사는 시장에서 입증되어 시장 참가자는 두 자릿수 성장을 바라보고 있습니다. 비용 절감, 치료 성적 향상, 심지어 항미생물제 내성과의 싸움에도 기여하고 있습니다.

세계의 증상 기반 다중진단(Syndromic Multiplex Diagnostic) 시장을 조사했으며, 시장 개요와 더불어 증후군, 위치, 제품, 국가별 동향 및 시장 진출기업 프로필 등을 제공합니다.

목차

제1장 시장 가이드

  • 상황 분석과 COVID 영향 개요
  • 임원 및 마케팅 직원을 위한 가이드
  • 투자 분석가 및 경영 컨설팅을 위한 가이드
  • 대기업 시장 점유율-표와 그래프

제2장 서론과 시장 정의

  • 증후군 멀티 플렉스 검사란 무엇인가
  • 증후군 검사-진단의 조용한 혁명
    • 증후군 검사
  • 시장 정의
    • 멀티 플렉스 시장 규모
    • 통화
  • 조사 방법
    • 저자
    • 소스
  • 전망 : 건강 관리, IVD 산업 및 COVID-19 유행
    • 세계의 보건 지출
    • 진단 지출
    • 진단을 위한 보험의 중요 역할

제3장 감염-병원체 가이드

  • 코로나 바이러스
    • 중증 급성 호흡기 증후군(SARS)
    • 중동 호흡기 증후군(MERS)
    • COVID-19
  • HIV-인간 면역 결핍 바이러스(AIDS)
    • 바이러스학
    • 진단
    • 검사
  • HBV-B형 간염
    • 바이러스학
    • 메커니즘
    • 진단
    • 시장 기회 분석
  • HCV-C형 간염
    • 분류
    • 분자생물학
    • 복제
    • 유전자형
    • 시장 기회 분석
  • 2.4HPV-인유두종 바이러스
    • 바이러스학
    • 진단
    • 시장 기회 분석
  • 독감
    • 바이러스학
    • 검사
    • 시장 기회 분석
  • CTGC-클라미디아/임질
    • 임질
    • 클라미디아
    • 검사
    • 시장 기회 분석
  • 결핵
    • 마이코 박테리아
    • 진단
    • 역학
    • 분자 진단 검사
    • 시장 기회 분석
  • MRSA-메티실린 내성 황색 포도상구균
    • 진단
    • FDA 승인 분자 검사
    • 시장 기회 분석
  • VRE-반코마이신 내성 장구균
    • VRE위한 FDA 승인 분자 진단 검사
    • 시장 기회 분석

제4장 산업의 개요

  • 업계 참가자
    • IVD 공급 업체
    • 독립 검사실 : 전문/난해한 분야
    • 독립 검사실 : 국가/지역
    • 독립 검사실 : 분석
    • 공립 국립/지역 연구소
    • 병원 검사실
    • 실천을위한 검사실
    • 감사 기관
  • 임상 검사 시장 부문
    • 기존 시장 세분화
    • 실험실의초점 및 세분화
    • 증후군 검사 시장 세분화
  • 산업 구조
    • 병원 검사 점유율
    • 규모의 경제
    • 실천을 위한 검사실
    • 의사와 POCT

제5장 시장 동향

  • 성장 촉진 요인
    • 진단 속도
    • 증후군 검사 비용에 미치는 영향
    • 포인트 오브 케어 장점
    • 증후군 검사 정확도 및 진단 위험
    • 1회 방문
    • 아웃 캠 개선
    • COVID-19 전염병 영향
  • 성장 억제 요인
    • 저렴한 가격
    • 관리/상환
    • 감염 감소
    • 건강 피해
    • 경제 성장에 따른 생활 수준 향상
    • 유행 불황 영향
  • 계측 및 자동화
    • 시장 점유율 핵심 장비
    • 수축 기계
    • 증후군 검사가 대형 기기로 전환
  • 진단 기술의 개발
    • Syndromictrends.com
    • 증후군과 표적 검사의 비교
    • 멀티 플렉스 패러다임의 변화
    • 패혈증 검사 시장-증후군의 선도자
    • 1 회 방문 및 항균 내성
    • 증후군 검사가 POCT의 채용을 촉진
    • PCR의 큰 미래

제6장 증후군 검사-신 개발

제7장 주요 증후군 검사 기업 프로필

제8장 세계의 증상 기반 다중진단 시장

  • 국가별 세계의 시장 개요
    • 표-국가별 세계의 시장
    • 차트-국가별 세계의 시장
  • 세계의 시장-증후군별-개요
    • 표-세계의 시장-증후군별
    • 차트-세계의 시장-증후군별-기준/마지막 학기의 비교
    • 차트-세계의 시장-증후군별-기준년도
    • 차트-세계의 시장-증후군별-연말
    • 차트-세계의 시장-증후군별-연도별 점유율
    • 차트-세계의 시장-증후군별-부문 성장
  • 세계의 시장-위치별-개요
    • 표-세계의 시장-위치별
    • 차트-세계의 시장-위치별-기준/마지막 학기의 비교
    • 차트-세계의 시장-위치별-기준년도
    • 차트-세계의 시장-위치별-연말
    • 차트-세계의 시장-위치별-연도별 점유율
    • 차트-세계의 시장-위치별-부문 성장
  • 세계의 시장-제품별-개요
    • 표-세계의 시장-제품별
    • 차트-세계의 시장-제품별-기준/최종 연도의 비교
    • 차트-세계의 시장-제품별-기준년도
    • 차트-세계의 시장-제품별-연말
    • 차트-세계의 시장-제품별-연도별 점유율
    • 차트-세계의 시장-제품별-부문 성장

제9장 세계의 증후군 멀티 플렉스 시장-증후군별

  • 호흡기
  • 소화관
  • 혈액
  • 수막염/뇌염
  • 성병
  • 기타

제10장 세계의 증후군 멀티 플렉스 시장-위치별

  • 병원 검사실
  • 외래 검사실
  • POC
  • 기타

제11장 세계의 증후군 멀티 플렉스 시장-제품별

  • 장치
  • 카트리지
  • 시약
  • 기타

제12장 부록

NJH 21.10.12

Table of Tables

  • Table 1 Market Share of Leading Companies
  • Table 2 Characteristics of Coronavirus Pandemic Infections
  • Table 3 COVID-19 Symptoms
  • Table 4 Classification of HIV Species
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 Influenza Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 Market Players by Type
  • Table 23 Clinical Laboratory Departments and Segments
  • Table 24 Laboratory Management Focus - Different Approaches
  • Table 25 Key Segmentation Variables Going Forward
  • Table 26 Possible Market Segments of Syndromic Multiplex Market
  • Table 27 Five Factors Driving Growth
  • Table 28 How SMT Improves Outcomes
  • Table 29 Four Factors Limiting Growth
  • Table 30 - Global Market by Region
  • Table 31 Global Market by Syndrome
  • Table 32 Global Market by Place
  • Table 33 Global Market by Product
  • Table 34 Respiratory by Country
  • Table 35 Gastrointestinal by Country
  • Table 36 Blood by Country
  • Table 37 Meningitis/Encephalitis by Country
  • Table 38 Sexually Transmitted Disease by Country
  • Table 39 Other by Country
  • Table 40 Hospital Lab by Country
  • Table 41 Outpatient Lab by Country
  • Table 42 Point of Care by Country
  • Table 43 Other by Country
  • Table 44 Instruments by Country
  • Table 45 Cartridges by Country
  • Table 46 Reagents by Country
  • Table 47 Other Product by Country
  • Table 48 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Market Share of Leading Companies Chart
  • Figure 2 The Global Healthcare Spending Picture
  • Figure 3 The Lab Test Pie
  • FIGURE 4 STRUCTURE OF CORONAVIRUSES
  • Figure 5 HIV Virion
  • Figure 6 Diagram of the HIV Replication Cycle
  • Figure 7 The Structure of the HBV Virus
  • Figure 8 Hepatitis B Replication
  • Figure 9 Structure of the HCV Virus
  • Figure 10 HCV Replication Cycle
  • Figure 11 Structure of the Influenza Virion
  • Figure 12 Influenza Replication
  • Figure 13 Scanning Electronmicrograph of Tuberculosis
  • Figure 14 Chart Death Rates and Infectious Disease Decline
  • Figure 15 Comparing Syndromic and Targeted Testing
  • Figure 16 The Multiplex Paradigm Shift
  • Figure 17 Global Market Share Chart
  • Figure 18 Global Market by Syndrome - Base vs. Final
  • Figure 19 Global Market by Syndrome Base Year
  • Figure 20 Global Market by Syndrome End Year
  • Figure 21 Syndrome Share by Year
  • Figure 22 Syndrome Segments Growth
  • Figure 23 Global Market by Place - Base vs. Final
  • Figure 24 Global Market by Place Base Year
  • Figure 25 Global Market by Place End Year
  • Figure 26 Place Share by Year
  • Figure 27 Place Segments Growth
  • Figure 28 Global Market by Product - Base vs. Final
  • Figure 29 Global Market by Product Base Year
  • Figure 30 Global Market by Product End Year
  • Figure 31 Product Share by Year
  • Figure 32 Product Segments Growth
  • Figure 33 Respiratory Growth
  • Figure 34 Gastrointestinal Diagnostics Growth
  • Figure 35 Blood Growth
  • Figure 36 Meningitis/Encephalitis Growth
  • Figure 37 Sexually Transmitted Disease Growth
  • Figure 38 Other Growth
  • Figure 39 Hospital Lab Growth
  • Figure 40 Outpatient Lab Growth
  • Figure 41 Point of Care Growth
  • Figure 42 Other Growth
  • Figure 43 Instruments Growth
  • Figure 44 Cartridges Growth
  • Figure 45 Reagents Growth
  • Figure 46 Other Product Growth

OVERVIEW:

The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out to 2025. In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel based ordering of infectious disease tests.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis & COVID Impact Overview
  • 1.2 Guide for Executives and Marketing Staff
  • 1.3 Guide for Investment Analysts and Management Consultants
  • 1.4 Market Shares of Leading Companies - Table and Chart

2 Introduction and Market Definition

  • 2.1 What are Syndromic Multiplex Tests?
  • 2.2 Syndromic Testing - the quiet revolution in diagnostics
    • 2.2.1 Syndromic Testing - more than Panels
  • 2.3 Market Definition
    • 2.3.1 Multiplex Market Size
    • 2.3.2 Currency
    • 2.3.3 Years
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Guide to the Pathogens

  • 3.1 The Coronavirus
    • 3.1.1 Severe acute respiratory syndrome (SARS)
    • 3.1.2 Middle East respiratory syndrome (MERS)
    • 3.1.3 COVID-19. The SARS CoV 2 Virus
      • 3.1.3.1 Signs and symptoms
      • 3.1.3.2 Transmission
      • 3.1.3.3 Diagnosis
      • 3.1.3.4 Prevention
      • 3.1.3.5 Management
      • 3.1.3.6 Prognosis
      • 3.1.3.7 New Strains and Subsequent Mutations
  • 3.3 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.3.1 Virology
      • 3.3.1.1 Classification
      • 3.3.1.2 Structure and genome
      • 3.3.1.3 Tropism
      • 3.3.1.4 Replication cycle
      • 3.3.1.5 Genetic variability
    • 3.3.2 Diagnosis
    • 3.3.3 Testing
      • 3.3.3.1 Antibody tests
      • 3.3.3.2 Point of Care Tests (POCT)
      • 3.3.3.3 Antigen Tests
      • 3.3.3.4 Nucleic acid-based tests (NAT)
      • 3.3.3.5 Other tests used in HIV treatment
  • 3.4 HBV - Hepatitis B
    • 3.4.1 Virology
      • 3.4.1.1 Genome
      • 3.4.1.2 Pathogenesis
      • 3.4.1.3 Hepatitis B virus replication
      • 3.4.1.4 Serotypes and genotypes
    • 3.4.2 Mechanisms
    • 3.4.3 Diagnosis
    • 3.4.4 Market Opportunity Analysis
  • 3.5 HCV - Hepatitis C
    • 3.5.1 Taxonomy
      • 3.5.1.1 Structure
      • 3.5.1.2 Genome
    • 3.5.2 Molecular biology
    • 3.5.3 Replication
    • 3.5.4 Genotypes
      • 3.5.4.1 Clinical importance
    • 3.5.5 Market Opportunity Analysis
  • 3.6 2.4 HPV - Human papillomavirus
    • 3.6.1 Virology
      • 3.6.1.1 E6/E7 proteins
      • 3.6.1.2 Role in cancer
      • 3.6.1.3 E2 research
      • 3.6.1.4 Latency period
      • 3.6.1.5 Clearance
    • 3.6.2 Diagnosis
      • 3.6.2.1 Cervical testing
      • 3.6.2.2 Oral testing
      • 3.6.2.3 Testing men
      • 3.6.2.4 Other testing
    • 3.6.3 Market Opportunity Analysis
  • 3.7 Influenza
    • 3.7.1 Virology
      • 3.7.1.1 Types of virus
      • 3.7.1.2 Influenzavirus A
      • 3.7.1.3 Influenzavirus B
      • 3.7.1.4 Influenzavirus C
      • 3.7.1.5 Structure, properties, and subtype nomenclature
      • 3.7.1.6 Replication
    • 3.7.2 Testing
      • 3.7.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.7.3 Market Opportunity Analysis
  • 3.8 CTGC - Chlamydia/Gonorhea
    • 3.8.1 Gonorrhea
      • 3.8.1.1 Diagnosis
      • 3.8.1.2 Screening
    • 3.8.2 Chlamydia
      • 3.8.2.1 Diagnosis
      • 3.8.2.2 Screening
    • 3.8.3 Testing
      • 3.8.3.1 Nucleic acid amplification tests (NAATs)
      • 3.8.3.2 Performance of NAAT Tests
    • 3.8.4 Market Opportunity Analysis
  • 3.9 Tuberculosis
    • 3.9.1 Mycobacteria
    • 3.9.2 Diagnosis
      • 3.9.2.1 Active tuberculosis
      • 3.9.2.2 Latent tuberculosis
    • 3.9.3 Epidemiology
    • 3.9.4 Molecular Diagnostic Tests
    • 3.9.5 Market Opportunity Analysis
  • 3.10 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.10.1 Diagnosis
    • 3.10.2 FDA Approved Molecular Tests
    • 3.10.3 Market Opportunity Analysis
  • 3.11 VRE - Vancomycin-resistant Enterococcus
    • 3.11.1 FDA Approved MDx Tests for VRE
    • 3.11.2 Market Opportunity Analysis

4 Industry Overview

  • 4.1 Industry Participants
    • 4.1.1 IVD Supplier
    • 4.1.2 Independent lab specialized/esoteric
    • 4.1.3 Independent lab national/regional
    • 4.1.4 Independent lab analytical
    • 4.1.5 Public National/regional lab
    • 4.1.6 Hospital lab
    • 4.1.7 Physician lab
    • 4.1.8 Audit body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
    • 4.2.3 Segmenting the Syndromic Testing Market
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
      • 4.3.2.1 Hospital vs. Central Lab
    • 4.3.3 Physician Office Lab's
    • 4.3.4 Physician's and POCT

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 Speed of Diagnosis
    • 5.1.2 Effect of Syndromic Testing on Costs
    • 5.1.3 Point of Care Advantage
    • 5.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
    • 5.1.5 Single Visits
    • 5.1.6 Improvement in Outcomes
    • 5.1.7 Impact of the COVID-19 Pandemic
  • 5.2 Factors Limiting Growth
    • 5.2.1 Lower Prices
    • 5.2.2 Administration/reimbursement
    • 5.2.3 Infectious Disease is Declining But...
    • 5.2.4 Wellness Hurts
    • 5.2.5 Economic Growth improves Living Standards
    • 5.2.6 Impact of the Pandemic Recession
  • 5.3 Instrumentation and Automation
    • 5.3.1 Instruments Key to Market Share
    • 5.3.2 The Shrinking Machine
    • 5.3.3 Syndrome Testing Moving to Big Instruments?
  • 5.4 Diagnostic Technology Development
    • 5.4.1 Syndromictrends.com
    • 5.4.2 Comparing Syndrome and Targeted Testing
    • 5.4.3 The Multiplex Paradigm Shift
    • 5.4.4 The Sepsis Testing Market - Bellwether for Syndromics
    • 5.4.5 The Single Visit and AntiMicrobial Resistance
    • 5.4.6 Syndromics drives POCT adoption
    • 5.4.7 A Big Future for PCR?

6 Syndromic Testing Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 QuantuMDx Developing Syndromic Panels for European Launch
  • 6.3 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
  • 6.4 QuantumDx Gets CE Mark for Rapid PoC PCR System
  • 6.5 Bio-Rad Laboratories, Seegene Partner for MDx Development
  • 6.6 Baebies to Expand Finder Platform
  • 6.7 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio
  • 6.8 Binx Health Targeting Clinics, DTC & OTC With STI Tests
  • 6.9 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
  • 6.10 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic
  • 6.11 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test
  • 6.12 New Approach Involves Silicon-Based Test for Infectious Disease Screening
  • 6.13 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test
  • 6.14 Qiagen sees NeuMoDx as Growth Vehicle
  • 6.15 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround
  • 6.16 Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests
  • 6.17 BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
  • 6.18 Infectious Disease Testing Firm Curative Acquires KorvaLabs
  • 6.19 ChromaCode Raises Additional $10M
  • 6.20 COVID-19 Patients Need Syndromic Testing
  • 6.21 GenMark Diagnostics - New Respiratory Panel due in June
  • 6.22 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
  • 6.23 Exact Diagnostics launches respiratory panel control
  • 6.24 bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA
  • 6.25 Nanomix Receives CE Mark for Diagnostic
  • 6.26 Applied BioCode Applies to FDA for Syndromic Respiratory Panel
  • 6.27 Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
  • 6.28 QIAGEN's New GI Panel Performance Assessed
  • 6.29 McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
  • 6.30 Applied BioCode Obtains FDA Clearance
  • 6.31 Meridian Bioscience to Acquire GenePOC Inc
  • 6.32 Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
  • 6.33 Qiagen gets FDA clearance for syndromic testing system
  • 6.34 Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux
  • 6.35 Akonni Biosystems Submits Multiplex Diagnostics System to FDA
  • 6.36 Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
  • 6.37 SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
  • 6.38 QuantuMDx and Molbio announce MoU
  • 6.39 Immunexpress Wins $745K Contract for Rapid Sepsis Assay
  • 6.40 Mobidiag Inks European, Middle Eastern Distribution Deals
  • 6.41 BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial

7 Profiles of Key Syndromic Testing Companies

  • 7.1 Abacus Diagnostica
  • 7.2 Abbott Diagnostics
  • 7.3 Accelerate Diagnostics
  • 7.4 Ador Diagnostics
  • 7.5 Akonni Biosystems
  • 7.6 Alveo Technologies
  • 7.7 Antelope Dx
  • 7.8 Applied BioCode
  • 7.9 Aus Diagnostics
  • 7.10 Baebies
  • 7.11 Beckman Coulter Diagnostics
  • 7.12 Becton, Dickinson and Company
  • 7.13 Binx Health
  • 7.14 Biocartis
  • 7.15 BioFire Diagnostics (bioMérieux)
  • 7.16 bioMérieux Diagnostics
  • 7.17 Bio-Rad Laboratories, Inc
  • 7.18 Bosch Healthcare Solutions GmbH
  • 7.19 Cepheid (Danaher)
  • 7.20 Credo Diagnostics Biomedical
  • 7.21 Cue Health
  • 7.22 Curetis N.V. / Curetis GmbH
  • 7.23 Diagenode Diagnostics
  • 7.24 Diasorin S.p.A
  • 7.25 Enzo Life Sciences, Inc
  • 7.26 Eurofins Scientific
  • 7.27 Fluxergy
  • 7.28 Fusion Genomics
  • 7.29 Genetic Signatures
  • 7.30 GenMark Dx (Roche)
  • 7.31 Hibergene Diagnostics
  • 7.32 Hologic
  • 7.33 Immunexpress
  • 7.34 Inflammatix
  • 7.35 Invetech
  • 7.36 Janssen Diagnostics
  • 7.37 Karius
  • 7.38 Lexagene
  • 7.39 LightDeck Diagnostics
  • 7.40 Lucira Health
  • 7.41 Luminex Corp
  • 7.42 Maxim Biomedical
  • 7.43 Meridian Bioscience
  • 7.44 Mesa Biotech (Thermo Fisher)
  • 7.45 Millipore Sigma
  • 7.46 Mobidiag (Hologic)
  • 7.47 Molbio Diagnostics
  • 7.48 Nanomix
  • 7.49 Novel Microdevices
  • 7.50 Operon
  • 7.51 Oxford Nanopore Technologies
  • 7.52 Panagene
  • 7.53 Perkin Elmer
  • 7.54 Primerdesign (Novacyt)
  • 7.55 Prominex
  • 7.56 Qiagen Gmbh
  • 7.57 Quantumdx
  • 7.58 Quidel
  • 7.59 Roche Molecular Diagnostics
  • 7.60 Saw Diagnostics
  • 7.61 Seegene
  • 7.62 Siemens Healthineers
  • 7.63 Sona Nanotech
  • 7.64 SpeeDx
  • 7.65 T2 Biosystems
  • 7.66 Talis Biomedical
  • 7.67 Thermo Fisher Scientific Inc
  • 7.68 Veramarx
  • 7.69 Visby Medical
  • 7.70 XCR Diagnostics

8 The Global Market for Syndromic Multiplex Diagnostics

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Syndrome - Overview
    • 8.2.1 Table - Global Market by Syndrome
    • 8.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Syndrome - Base Year
    • 8.2.4 Chart - Global Market by Syndrome - End Year
    • 8.2.5 Chart - Global Market by Syndrome - Share by Year
    • 8.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 8.3 Global Market by Place - Overview
    • 8.3.1 Table - Global Market by Place
    • 8.3.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 8.3.3 Chart - Global Market by Place - Base Year
    • 8.3.4 Chart - Global Market by Place - End Year
    • 8.3.5 Chart - Global Market by Place - Share by Year
    • 8.3.6 Chart - Global Market by Place - Segments Growth
  • 8.4 Global Market by Product - Overview
    • 8.4.1 Table - Global Market by Product
    • 8.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 8.4.3 Chart - Global Market by Product - Base Year
    • 8.4.4 Chart - Global Market by Product - End Year
    • 8.4.5 Chart - Global Market by Product - Share by Year
    • 8.4.6 Chart - Global Market by Product - Segments Growth

9 Global Syndromic Multiplex Markets - By Syndrome

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Gastrointestinal
    • 9.2.1 Table Gastrointestinal - by Country
    • 9.2.2 Chart - Gastrointestinal Growth
  • 9.3 Blood
    • 9.3.1 Table Blood - by Country
    • 9.3.2 Chart - Blood Growth
  • 9.4 Meningitis/Encephalitis
    • 9.4.1 Table Meningitis/Encephalitis - by Country
    • 9.4.2 Chart - Meningitis/Encephalitis Growth
  • 9.5 Sexually Transmitted Disease
    • 9.5.1 Table Sexually Transmitted Disease - by Country
    • 9.5.2 Chart - Sexually Transmitted Disease Growth
  • 9.6 Other Syndrome
    • 9.6.1 Table Other - by Country
    • 9.6.2 Chart - Other Growth

10 Global MDx Infectious Disease Markets - by Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Outpatient Lab
    • 10.2.1 Table Outpatient Lab - by Country
    • 10.2.2 Chart - Outpatient Lab Growth
  • 10.3 Point of Care
    • 10.3.1 Table Point of Care - by Country
    • 10.3.2 Chart - Point of Care Growth
  • 10.4 Other Place
    • 10.4.1 Table Other - by Country
    • 10.4.2 Chart - Other Place Growth

11 Global MDx Infectious Disease Markets - by Product

  • 11.1 Instruments
    • 11.1.1 Table Instruments - by Country
    • 11.1.2 Chart - Instruments Growth
  • 11.2 Cartridges
    • 11.2.1 Table Cartridges - by Country
    • 11.2.2 Chart - Cartridges Growth
  • 11.3 Reagents
    • 11.3.1 Table Reagents - by Country
    • 11.3.2 Chart - Reagents Growth
  • 11.4 Other Product
    • 11.4.1 Table Other Product - by Country
    • 11.4.2 Chart - Other Product Growth

12 Appendices

  • 12.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule
Back to Top
전화 문의
F A Q